An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

The Principal Investigator hypothesizes the combination of MIRV and Olaparib is an effective, and tolerable, maintenance therapy strategy in platinum sensitive recurrent ovarian cancer.

Trial Details

NCT ID
NCT05887609
Phase
PHASE2
Sponsor
University of Colorado, Denver
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Mirvetuximab Soravtansine-gynx
  • Olaparib
Locations (sample)
  • Aurora, Colorado, United States|39.72943,-104.83192
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362
  • Pittsburgh, Pennsylvania, United States|40.44062,-79.99589
  • Madison, Wisconsin, United States|43.07305,-89.40123

Key Eligibility Criteria

  • Provision to sign and date the consent form
  • Stated willingness to comply with all study procedures and be available for the duration of the study
  • Be a woman aged ≥18 years of age
  • Patients must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →